R-ESHAP regimen
WikiDoc Resources for R-ESHAP regimen |
Articles |
---|
Most recent articles on R-ESHAP regimen Most cited articles on R-ESHAP regimen |
Media |
Powerpoint slides on R-ESHAP regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on R-ESHAP regimen at Clinical Trials.gov Trial results on R-ESHAP regimen Clinical Trials on R-ESHAP regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on R-ESHAP regimen NICE Guidance on R-ESHAP regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on R-ESHAP regimen Discussion groups on R-ESHAP regimen Patient Handouts on R-ESHAP regimen Directions to Hospitals Treating R-ESHAP regimen Risk calculators and risk factors for R-ESHAP regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for R-ESHAP regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Etoposide, Solumedrol (Methylprednisolone) High-dose Ara-C (Cytarabine), Platinol (Cisplatin)
Overview
R-ESHAP regimen refers to a salvage regimen consisting of rituximab, etoposide, (Solumedrol, high-dose), cytarabine (Ara-C), and cisplatin (Platinol) used to treat refractory diffuse large B-cell lymphoma.[1]
Regimen
RRituximab
EEtoposide
SHMethypredisolone (Solumedrol), High-dose
ACytarabine (Ara C)
PCisplatin (Platinol)
Indications
References
- ↑ 1.0 1.1 Martín A, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (2009). "R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome". Haematologica. 94 (5): 744. doi:10.3324/haematol.2009.006452. PMC 2675691. PMID 19336744.